Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes

Joshua J. Meeks*, Hikmat Al-Ahmadie, Bishoy M. Faltas, John A. Taylor, Thomas W. Flaig, David J. DeGraff, Emil Christensen, Benjamin L. Woolbright, David J. McConkey, Lars Dyrskjøt

*Corresponding author for this work

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

Histological and molecular analyses of urothelial carcinoma often reveal intratumoural and intertumoural heterogeneity at the genomic, transcriptional and cellular levels. Despite the clonal initiation of the tumour, progression and metastasis often arise from subclones that can develop naturally or during therapy, resulting in molecular alterations with a heterogeneous distribution. Variant histologies in tumour tissues that have developed distinct morphological characteristics divergent from urothelial carcinoma are extreme examples of tumour heterogeneity. Ultimately, heterogeneity contributes to drug resistance and relapse after therapy, resulting in poor survival outcomes. Mutation profile differences between patients with muscle-invasive and metastatic urothelial cancer (interpatient heterogeneity) probably contribute to variability in response to chemotherapy and immunotherapy as first-line treatments. Heterogeneity can occur on multiple levels and averaging or normalizing these alterations is crucial for clinical trial and drug design to enable appropriate therapeutic targeting. Identification of the extent of heterogeneity might shape the choice of monotherapy or additional combination treatments to target different drivers and genetic events. Identification of the lethal tumour cell clones is required to improve survival of patients with urothelial carcinoma.

Original languageEnglish (US)
Pages (from-to)259-270
Number of pages12
JournalNature Reviews Urology
Volume17
Issue number5
DOIs
StatePublished - May 1 2020

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes'. Together they form a unique fingerprint.

Cite this